WIN378 for COPD

(Sirius Trial)

This trial tests a new medicine called WIN378 to aid individuals with moderate to severe chronic obstructive pulmonary disease (COPD). Researchers aim to determine the optimal dose of this medicine, which blocks a protein responsible for lung inflammation. The study will examine how the body processes WIN378 and assess its safety, effects on lung health, and COPD symptoms. Individuals with COPD who are former smokers and have maintained stable inhaled therapy might be suitable candidates. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.

The trial requires participants to be on stable triple inhaled therapy (ICS/LABA/LAMA) for at least 3 months, so you will need to continue taking these medications. If you have been on any biologic therapies for COPD, there is a required washout period (time without taking these medications) of at least 5 half-lives before joining the study.

Research has shown that WIN378 was safe in earlier studies. These studies tested WIN378 in various conditions, including advanced solid tumors, and found it was generally well-tolerated, meaning most participants did not experience severe side effects. The trials also suggested that WIN378 could serve as a long-lasting treatment targeting TSLP, a protein linked to lung inflammation.

Unlike the standard treatments for COPD, which typically include bronchodilators and corticosteroids, WIN378 is unique because it is delivered through subcutaneous (SC) injections. This method targets inflammation in a novel way, potentially offering more direct and sustained relief. Researchers are excited about WIN378 because it could provide a new option for patients who don't respond well to existing treatments, offering hope for improved management of COPD symptoms.

Research shows that WIN378, which participants in this trial may receive, could help treat COPD by blocking a protein called TSLP, which causes lung inflammation. Studies of similar treatments targeting proteins like TSLP have shown varying success in people with asthma and COPD. By reducing inflammation, WIN378 might improve lung function and manage COPD symptoms. Early results from other trials suggest that targeting TSLP can effectively address similar breathing problems.¹⁶⁷⁸⁹